Terence Ware Friedlander, MS

Terence Friedlander practices at Zuckerberg San Francisco General Hospital and Trauma Center in San Francisco, California, part of City and County of San Francisco, CA.

Terence Friedlander's NPI, 1215134267, was assigned on July 2, 2007. Terence Friedlander graduated from New York University School of Medicine in 2003. Terence Friedlander holds California license A88888.

Terence Friedlander's primary practice is Zuckerberg San Francisco General Hospital and Trauma Center, at 1001 Potrero Avenue, San Francisco, CA 94110 in San Francisco County. The practice phone is (415) 206-8000.

Terence Friedlander's primary practice is Zuckerberg San Francisco General Hospital and Trauma Center in San Francisco, California, part of City and County of San Francisco, CA. Terence Friedlander is also affiliated with UCSF Helen Diller Medical Center at Parnassus Heights. The medical group on file is UCSF Pediatrics. Dmand AI also links Terence Friedlander to 4 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Terence Friedlander practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Terence Friedlander's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Terence Friedlander is board certified in medical oncology by the American Board of Internal Medicine. Terence Friedlander is licensed in California.

Dmand AI lists multiple myeloma and prostate cancer among the conditions Terence Friedlander treats.

CMS data shows 363 Medicare services from Terence Friedlander across 4 procedure codes in 2024, for 122 Medicare patients. Medicare paid $22,793 for them.

CMS counts 122 Medicare patients who saw Terence Friedlander in 2024. The largest group is 75 to 84, with 59 patients. 75% of them have cancer, and 70% have high cholesterol. 18% are also on Medicaid. Their average risk score is 2.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Terence Friedlander's median patient age at 73, with 23% women.

In 2024, Terence Friedlander wrote 445 Medicare Part D claims for 74 patients. 76% of them were for generic drugs. CMS names the drug for 245 of them, across 9 drugs with 11 or more claims each, at $730,479 in total drug cost. In 2023, CMS named 322 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Terence Friedlander for performance year 2024, reported as part of a group. Terence Friedlander accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Terence Friedlander as offering telehealth.

Dmand AI links 64 papers to Terence Friedlander, published from 2010 to 2025. 2021 was the busiest year, with 9. The most frequent topics are Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant and Urinary Bladder Neoplasms. Terence Friedlander has published most often in Clin Cancer Res. Terence Friedlander's most frequent co-authors are Eric J. Small, MD, Rahul R. Aggarwal, MD and Vadim S. Koshkin, MD.

CMS Open Payments shows 309 general payments to Terence Friedlander from 25 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 57% of the total. Astellas Pharma Europe Ltd paid the most, $49,112. It also lists 10 research payments totaling $12,603 from 2019 to 2025.

Terence Friedlander graduated from New York University School of Medicine in 2003.

Terence Friedlander is in network with 10 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.